Penelope A Bradbury
Overview
Explore the profile of Penelope A Bradbury including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
948
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lone A, Salunkhe R, Sugumar V, Zhan L, Ye X, Bezjak A, et al.
Clin Transl Radiat Oncol
. 2025 Feb;
51:100917.
PMID: 39898331
Background: The role of prophylactic cranial irradiation (PCI) is not well-defined in extensive-stage SCLC (ES-SCLC), with conflicting results from randomized trials and a lack of relevant data for patients who...
2.
Kindler H, Ismaila N, Bazhenova L, Chu Q, Churpek J, Dagogo-Jack I, et al.
J Clin Oncol
. 2025 Jan;
43(8):1006-1038.
PMID: 39778125
Purpose: To provide evidence-based recommendations to practicing physicians and others on the management of pleural mesothelioma (PM). Methods: ASCO convened an Expert Panel of medical oncology, thoracic surgery, radiation oncology,...
3.
Ghazali N, Feng J, Hueniken K, Khan K, Balaratnam K, Waddell T, et al.
Ther Adv Med Oncol
. 2024 Dec;
16:17588359241308466.
PMID: 39734710
Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted...
4.
Schmid S, Garcia M, Zhan L, Cheng S, Khan K, Chowdhury M, et al.
Heliyon
. 2024 Sep;
10(17):e37082.
PMID: 39296139
Background: We evaluated outcomes in non-small cell lung cancer (NSCLC) patients who presented with brain-only metastatic (BOM) disease overall and by EGFR/ALK mutation status. Methods: We analyzed clinico-demographic, treatment and...
5.
Barghout S, Zhan L, Raptis S, Al-Agha F, Esfahanian N, Popovacki A, et al.
Lung Cancer
. 2024 Jul;
194:107898.
PMID: 39074423
Objectives: KRAS mutations, particularly KRAS, are prevalent in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have been a frontline treatment, but recently developed KRAS-selective inhibitors, such as sotorasib,...
6.
Schmid S, Zhan L, Garcia M, Dietrich K, Khan K, Chowdhury M, et al.
Clin Lung Cancer
. 2024 Jun;
25(7):e277-e285.e3.
PMID: 38825405
Background: The 2018 ASCO pleural mesothelioma (PM) treatment guideline states that "a trial of expectant observation may be offered" in patients with asymptomatic inoperable epithelioid mesothelioma with low disease burden....
7.
Esfahanian N, Chan S, Zhan L, Brown M, Khan K, Lee J, et al.
Cancer Treat Res Commun
. 2023 Nov;
37:100774.
PMID: 37979334
Close monitoring after diagnosis of patients with stage I-III non-small cell lung cancer (NSCLC) may result in fitter patients with lower disease burden at the time of metastatic recurrence or...
8.
Anagnostou V, Ho C, Nicholas G, Juergens R, Sacher A, Fung A, et al.
Nat Med
. 2023 Oct;
29(10):2559-2569.
PMID: 37814061
Circulating tumor DNA (ctDNA) has shown promise in capturing primary resistance to immunotherapy. BR.36 is a multi-center, randomized, ctDNA-directed, phase 2 trial of molecular response-adaptive immuno-chemotherapy for patients with lung...
9.
Lau S, Perdrizet K, Fung A, Mata D, Weiss J, Holzapfel N, et al.
JTO Clin Res Rep
. 2023 Sep;
4(10):100562.
PMID: 37744308
Introduction: NSCLC with exon 14 skipping mutation (ex14) is associated with poor outcomes. Integration of novel targeted therapies is challenging because of barriers in testing and drug access. We, therefore,...
10.
Garcia-Pardo M, Czarnecka-Kujawa K, Law J, Salvarrey A, Fernandes R, Fan Z, et al.
JAMA Netw Open
. 2023 Jul;
6(7):e2325332.
PMID: 37490292
Importance: Liquid biopsy has emerged as a complement to tumor tissue profiling for advanced non-small cell lung cancer (NSCLC). The optimal way to integrate liquid biopsy into the diagnostic algorithm...